Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.pharmaceutical-technology.com/news/xilio-fires-21-of-its-workforce-and-reprioritises-pipeline/
https://www.globenewswire.com/news-release/2024/04/01/2855434/0/en/Xilio-Therapeutics-Announces-Pipeline-and-Business-Updates-and-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com/news-release/2024/03/28/2853858/0/en/Xilio-Therapeutics-Announces-11-3-Million-Private-Placement-Equity-Financing.html
https://www.globenewswire.com//news-release/2024/02/28/2837389/0/en/Xilio-Therapeutics-to-Participate-in-Novel-Immuno-Oncology-Panel-at-TD-Cowen-44th-Annual-Health-Care-Conference.html
https://www.globenewswire.com/news-release/2024/01/31/2821540/0/en/Xilio-Therapeutics-to-Present-at-Guggenheim-6th-Annual-Biotechnology-Conference.html
https://www.globenewswire.com//news-release/2024/01/08/2805332/0/en/Xilio-Therapeutics-Highlights-Recent-Advances-Across-Clinical-Pipeline-and-Encouraging-Preliminary-Phase-1-Safety-Data-for-XTX301-a-Tumor-Activated-IL-12-Further-Validating-the-Pro.html
https://www.globenewswire.com//news-release/2023/12/07/2792409/0/en/Xilio-Therapeutics-Announces-Initiation-of-Enrollment-for-Phase-1-Combination-Trial-of-XTX101-a-Tumor-Activated-Fc-Enhanced-Anti-CTLA-4-and-Updated-Phase-1-Monotherapy-Data.html
https://www.globenewswire.com//news-release/2023/11/09/2777773/0/en/Xilio-Therapeutics-Announces-Pipeline-and-Business-Updates-and-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/11/03/2773330/0/en/Xilio-Announces-Initial-Monotherapy-Safety-and-Anti-Tumor-Activity-Data-for-XTX202-a-Tumor-Activated-Engineered-Beta-Gamma-IL-2-in-Late-Line-Patients-with-Advanced-Solid-Tumors.html